OVID Ovid Therapeutics Inc.

+0.07  (+4%)
Previous Close 1.86
Open 1.88
Price To Book 1.65
Market Cap 74,677,525
Shares 38,693,018
Volume 100,750
Short Ratio
Av. Daily Volume 316,333

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due YE 2019 or early 2020.
OV101 (gaboxadol)
Fragile X syndrome
Phase 2 open label data due 3Q 2019.
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 data due mid-2020.
Adolescents with Angelman syndrome
Phase 2 trial continues to enrol as of August 2019.
Dravet Syndrome / Lennox-Gastaut Syndrome
Phase 1b/2a data due 1Q 2020.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
  2. Some Ovid Therapeutics (NASDAQ:OVID) Shareholders Have Taken A Painful 71% Share Price Drop
  3. Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
  4. Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
  5. Ovid Therapeutics to Host R&D Day on June 27, 2019
  6. Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium
  7. Ovid Therapeutics Reports First Quarter 2019 Financial Results
  8. Ovid Therapeutics Rallies On Rare Genetic Disorder Drug Data
  9. Have Insiders Been Buying Ovid Therapeutics Inc. (NASDAQ:OVID) Shares This Year?
  10. Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
  11. Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
  12. Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
  13. Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  14. Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
  15. Why A Secondary Offering Is Often Negative For Stocks
  16. Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
  17. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  18. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
  19. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  20. How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?